• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconTerm Sheet

Term Sheet

Page 29 of 100
Fortune’s Term Sheet newsletter covers the latest news, insights, and analysis on private equity, venture capital, start-ups, mergers and acquisitions, high-value deals, and the dealmakers behind them. Subscribe to receive Term Sheet in your inbox every weekday morning. Sign up here.
middle-aged man wearing blue t-shirt speaking during an interview
NewslettersAn inside look at one of Silicon Valley’s most mysterious venture funds
By Jessica MathewsJuly 23, 2024
NewslettersExclusive: Lauri Moore joins Bessemer as partner
By Allie GarfinkleJuly 22, 2024
empty chairs surround a brightly lit conference stage
NewslettersWhat GPs and LPs say to each other behind closed doors
By Allie GarfinkleJuly 19, 2024
NewslettersHow to communicate with Gen Z: “Be more vulnerable than you think you need to be”
By Allie GarfinkleJuly 18, 2024
NewslettersAre AI’s lofty valuations justified? Some VCs think it is
By Luisa BeltranJuly 17, 2024
NewslettersWhat you need to know about J.D. Vance’s VC career
By Allie GarfinkleJuly 16, 2024
NewslettersA new credit card for NYC millionaires has over 30,000 people on the waitlist
By Allie GarfinkleJuly 15, 2024
NewslettersAI startups raised $24 billion globally in Q2, but the question remains: Where will value in AI accrue? Here’s one VC’s (slightly) contrarian take.
By Allie GarfinkleJuly 12, 2024
NewslettersExclusive: Armada lands $40 million in funding round led by Microsoft’s M12
By Allie GarfinkleJuly 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
NewslettersAs more and more weight-loss startups prescribe Ozempic and Wegovy, doctors say they’re making unproven claims
By Jessica Mathews and Alena BotrosJuly 10, 2024
NewslettersExclusive: Canoe Intelligence raises $36 million for Series C led by Goldman Sachs
By Allie GarfinkleJuly 9, 2024
NewslettersHow whaling ventures in the 1800s shaped venture capital as we know it
By Allie GarfinkleJuly 8, 2024
NewslettersFintech is likely to face increased scrutiny after Evolve hack
By Allie GarfinkleJuly 5, 2024
NewslettersWhy Universal Hydrogen folded—and why the company’s mission will live on
By Allie GarfinkleJuly 3, 2024
NewslettersThe AI startups of VCs’ dreams, from recruiting to an Nvidia alternative
By Allie GarfinkleJuly 2, 2024
1...
  • 27
  • 28
  • 29
  • 30
  • 31
...100
Most Popular
Europe
413,793 KitKat bars stolen: 'Whilst we appreciate the criminals’ exceptional taste, the fact remains that cargo theft is an escalating issue'An image of a popular article
By Fortune EditorsMarch 28, 2026
Energy
Elon Musk warns the U.S. could soon be producing more chips than we can turn on. And China doesn’t have the same issueAn image of a popular article
By Fortune EditorsMarch 29, 2026
Energy
Saudi pipeline to bypass Hormuz hits 7 million barrel goalAn image of a popular article
By Fortune EditorsMarch 28, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.